<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors retrospectively analyzed the records of 33 children with acquired severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) diagnosed from July 1998 to October 2007 and first treated by immunosuppressive therapy (IST) </plain></SENT>
<SENT sid="1" pm="."><plain>Serial hematologic parameters, complications, transfusion requirements, and time to response were assessed </plain></SENT>
<SENT sid="2" pm="."><plain>Allogeneic hematopoietic stem cell transplantation (HSCT) was attempted in 7 patients after failure of IST (n = 6) or relapse following an initial response to IST (n = 1) </plain></SENT>
<SENT sid="3" pm="."><plain>One child died of post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty of the 33 patients are alive and well after a median follow-up of 45 months (range, 7-116 months) </plain></SENT>
<SENT sid="5" pm="."><plain>Overall (transfusion-independent) response to IST was 73% (24/33) </plain></SENT>
<SENT sid="6" pm="."><plain>The actuarial 5 years survival rate was 89.4% </plain></SENT>
<SENT sid="7" pm="."><plain>In this study, <z:hpo ids='HP_0000001'>all</z:hpo> patients with SAA received IST as standard front-line therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Approximately three-fourths of patients with SAA have durable recovery and excellent overall survival </plain></SENT>
</text></document>